Aktuellt
SENASTE
Redeye raises its fair value range following a review of BONESUPPORT’s long-term potential. Our updated and lengthened financial forecast better reflects the company’s strong value proposition, which we believe positions CERAMENT well for becoming a paradigm shift driver towards locally eluting antibiotic synthetic bone grafts in bone defect treatment.
LÄS MER
